Tokyo, July 6, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the fifth consecutive year to be included in the FTSE4Good Index Series, one of the world’s premier indices for socially responsible investment.

Managed by FTSE Russell, the FTSE4Good Index Series serves as a major criterion for investors around the world in assessing social responsibility activities by the companies, when making investment decisions. As of June 30, 2016, 823 companies from around the world, including 160 Japanese companies, were selected as the constituents of this index. FTSE Russell uses unique criteria which contain 14 themes relevant to environmental, social and governance practices. The FTSE4Good Index Series, together with the Dow Jones Sustainability Index, are the most recognized sustainability indices worldwide.

Through a wide range of CSR activities, Astellas will continue to strive to create and protect social value, contribute to the sustainable development of society and consequently enhance its enterprise value.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.